BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, June 4, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 23, 2017
View Archived Issues
Pan-CK2 inhibitor BMS-159 chosen for development as anticancer candidate
Read More
IdeS reduces donor-specific antibodies allowing for HLA-incompatible transplantation
Read More
Genentech presents data from phase I trial of influenza B candidate MHAB-5553A
Read More
BMP inhibition a novel pharmacological strategy for multiple hereditary exostoses
Read More
Trisubstituted benzene CGRP antagonists for migraine created at Merck & Co.
Read More
PharmAkea completes phase I study of PAT-1251
Read More
New phase IIa trial tests S. hominis lotion for atopic dermatitis
Read More
Sun Pharma Advanced Research discovers novel Bruton tyrosine kinase inhibitors
Read More
Pharmakea presents new lysyl oxidase homolog 2 inhibitors
Read More
Takeda submits Japanese NDA for vedolizumab for ulcerative colitis
Read More
FDA grants orphan drug designation to Jotrol for Friedreich's ataxia
Read More
CIRM grant supports Cellerant's development of CLT030-ADC for AML
Read More
Phase Ib results reported for proinsulin peptide immunotherapy in subjects with type 1 diabetes
Read More
AC Immune expands neurodegenerative pipeline with new antibodies against alpha-synuclein and TDP-43
Read More
Topas signs research and option agreement with Lilly focused on antigen-specific tolerance induction
Read More
Janssen describes synthesis of GPR40 full agonists for type 2 diabetes
Read More
CRISPR Therapeutics and Massachusetts General Hospital collaborate to develop T-cell therapies
Read More
Obesity compounds begin phase I trials under Zealand and Boehringer Ingelheim collaboration
Read More
Phase III study of Ace-ER in GNE myopathy misses primary endpoint
Read More
